93.78 0.00 (0.00%)
After hours: 6:16PM EST
|Bid||93.81 x 300|
|Ask||96.00 x 800|
|Day's Range||93.71 - 95.55|
|52 Week Range||88.32 - 147.17|
|PE Ratio (TTM)||25.76|
|Earnings Date||Apr 25, 2018 - Apr 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||125.31|
Merck (MRK) to buy Australian oncolytic immunotherapies maker Viralytics Limited to strengthen its presence in the fast growing immuno-oncology market.
Celgene Corporation today announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the previously announced tender offer by Celgene’s wholly owned subsidiary, Blue Magpie Corporation, for all issued and outstanding shares of common stock of Juno Therapeutics, Inc.
Novartis: What Are the Major Growth Drivers for 2018? On October 31, 2017, Novartis (NVS) announced the submission of a supplemental biologics license application (or sBLA) to the FDA. The sBLA seeks approval for Kymriah as a treatment option for adult patients with relapsed/refractory diffuse large B-cell lymphoma (or r/r DLBCL).
Novartis: What Are the Major Growth Drivers for 2018? On August 30, 2017, Novartis’ (NVS) CAR T-cell therapy, Kymriah, secured approval from the FDA as a treatment option for patients below 25 years of age who have B-cell precursor acute lymphoblastic leukemia (or ALL). This drug, which is developed by the company in collaboration with the University of Pennsylvania, is indicated only in cases when ALL is refractory or has relapsed a second time or more.
Celgene (CELG) is looking to expand dermatology drug Otezla's label and reported positive data from a late-stage study in patients with active Beh??et???s Disease.
Celgene Corporation today announced that data from the phase III RELIEF™ clinical trial of OTEZLA® in patients with active Behçet’s Disease with oral ulcers were presented in a late-breaking oral presentation at the 2018 American Academy of Dermatology Annual Meeting.
Celgene Corporation (NASDAQ:CELG) delivered an ROE of 42.48% over the past 12 months, which is an impressive feat relative to its industry average of 16.36% during the same period. WhileRead More...
This year could be big for biotech mergers after Celgene and Sanofi, in a few days, spent $25 billion for three companies.
Bridgewater Associates, the firm of hedge fund billionaire Ray Dalio, took large positions in ETFs, 13F filings show.
College Retirement Equities Fund, known as TIAA, has reached its 100th year since being founded by Andrew Carnegie. Teachers Advisors, an investment advisor unit of TIAA, turns a mere 25 this year. It manages $78 billion in U.S.-traded securities, and in the fourth quarter it made some bold stock trades that showed it has nerves of steel.
WARREN, N.J. , Feb. 15, 2018 /PRNewswire/ -- Celularity has been created through the contribution and acquisition of extensive intellectual property, clinical-stage assets, basic and clinical research, ...
Celgene Corporation announced that data from a randomized, placebo-controlled, multi-center, phase II clinical trial of apremilast in patients with active ulcerative colitis who had failed at least one conventional therapy but were naïve to biologic therapy were presented in an oral session today at the 13th Congress of ECCO in Vienna (Abstract OP006, 3:30 p.m.
Celularity, a company spun out of biotech giant Celgene, announced this morning it has raised $250 million with the aim of developing cells from placentas to attack tumors and to treat Crohn’s disease. In addition to being awash in cash, the company is flooded with big dreams.
Peter Diamandis, Celularity co-founder and vice chairman, and Bob Hariri, Celularity co-founder, chairman and CEO, talk about the future of cellular medicine as scientist develop ways to reengineer living cells.